Resin in the Tablets: What the Novo-Gesic Forte Recall Reveals About Packaging and Equipment Material Controls

On 10 September 2026, Teva Canada Limited recalled a lot of Novo-Gesic Forte 500 mg acetaminophen because it may contain phenolic resin or epoxy. Health Canada classified it as a Type I recall, its most serious category, because ingesting the material could injure the digestive system. For most consumers this reads as another pharmacy recall. For a quality professional, it reads as something more specific and more preventable: a failure of contact-material control, where a substance that should never have touched the product found its way into a solid oral dose.

This recall is not a formulation problem, a cross contamination event, or a line clearance mix up. Those failure modes have their own controls. This is about the materials that equipment surfaces, packaging components, and closures are made of, and the requirement that none of them react with, add to, or absorb the product. This article explains what that requirement is, where phenolic resin and epoxy come from in a manufacturing line, how to run a defensible root cause investigation, and the controls that keep contact materials from becoming a Type I recall.

Executive summary

A single lot of a common pain reliever was pulled from the national market because of a contact-material contaminant, not the active ingredient. Under both Canadian and United States good manufacturing practice, every surface that touches a drug product, and every container and closure, must be non reactive, non additive, and non absorptive. Phenolic resin and epoxy are found in equipment coatings, tank and pipe linings, filter housings, gaskets, and closure liners. When one of them degrades, is misapplied, or is substituted without control, it can shed into product. The fix is not reactive testing after the fact. It is material qualification, change control, and supplier oversight built in before the first batch.

What happened in the Novo-Gesic Forte recall?

What it is: Teva Canada recalled one lot of Novo-Gesic Forte 500 mg acetaminophen because it may contain phenolic resin or epoxy. Why it matters: acetaminophen is one of the most widely used medicines in Canada, and a Type I classification signals a serious potential hazard, not a labelling technicality. What to do: any manufacturer or packager of solid oral doses should treat this as a prompt to review its own contact-material controls, because the failure mode is not unique to one company. How it affects compliance: a Type I recall triggers regulatory scrutiny, a root cause investigation, and corrective and preventive action that an inspector will later expect to see fully documented.

The recall is national. The affected product was supplied to pharmacies in 1,000 count bottles and dispensed to patients in smaller quantities, which is why the notice reached the consumer press. Health Canada's recall notice states the hazard plainly: the material, if ingested, may cause injury to the digestive system.

What does a Type I recall mean?

What it is: a Type I recall is the most serious of the three Canadian recall classes. Why it matters: Health Canada assigns Type I when there is a reasonable probability that the use of, or exposure to, a product will cause serious adverse health consequences or death. What to do: understand that classification drives the depth of the response, the recall reach, and the level of documentation Health Canada expects. How it affects compliance: a Type I event almost always leads to a health hazard evaluation, an effectiveness check on the recall itself, and a corrective and preventive action plan that must address root cause, not just the affected lot.

Type II covers situations where the health consequences are temporary or reversible, or where the probability of serious harm is remote. Type III covers products unlikely to cause any adverse health consequence but that still breach a regulation. A contaminant that could injure the digestive tract sits clearly in Type I. For a deeper treatment of how Canada classifies recalls and what each class signals, see our guide below.

What is packaging and equipment material control?

What it is: contact-material control is the GMP requirement that anything touching the drug product, whether an equipment surface, a container, or a closure, must not change the product. Why it matters: a reactive, additive, or absorptive material can leach chemicals into the dose, remove a component from it, or degrade over time and shed particles. What to do: qualify every contact material before use and control any change to it. How it affects compliance: this requirement is explicit in both Canadian and United States GMP, so a contact-material failure is a direct GMP deviation, not a grey area.

In the United States, 21 CFR 211.65 requires that equipment surfaces contacting components, in process materials, or drug products not be reactive, additive, or absorptive so as to alter the product. 21 CFR 211.94 sets the same standard for drug product containers and closures. In Canada, the equivalent expectations sit in Division 2 of the Food and Drug Regulations and are explained in Health Canada's Good Manufacturing Practices Guide, GUI-0001, which addresses equipment construction and the control of packaging materials.

Why do phenolic resin and epoxy matter?

What it is: phenolic resin and epoxy are hard, durable materials used across manufacturing equipment for coatings, linings, adhesives, and molded components. Why it matters: they are chosen precisely because they are tough, but when they are the wrong grade, are incompletely cured, degrade with age, or are introduced during an uncontrolled repair, they can shed particles or leach chemicals into product. What to do: know where these materials exist in your line and treat any change to them as a formal change. How it affects compliance: an unqualified or degraded contact material is a defect in the manufacturing system, which is exactly what a root cause investigation must expose.

Root cause and CAPA: how to investigate a contact-material contamination

What it is: a structured investigation that identifies the actual source of the material and the system weakness that allowed it. Why it matters: closing a recall on the affected lot alone, without finding why the material entered, invites the same failure again. What to do: trace the material to its source, then ask why the control that should have prevented it did not work. How it affects compliance: 21 CFR 211.192 and its Canadian equivalents require a thorough investigation of any unexplained discrepancy, and inspectors read a shallow investigation as a quality system failure in its own right.

A defensible investigation identifies the material, maps every point in the process where that material is present, and confirms which control failed. Material identification through laboratory analysis is the anchor, because you cannot map a source you have not confirmed. From there, the investigation moves through equipment, components, and maintenance history, then into change control and supplier records. Our guide to getting the batch failure investigation right explains the standard that regulators apply.

How to prevent a contact-material recall

What it is: a set of front loaded controls that qualify materials and govern change before a defect can reach product. Why it matters: end product testing rarely detects a contact-material contaminant, because the sampling plan is not designed to find it. What to do: qualify materials, assess extractables and leachables where the risk warrants it, and lock down change control and supplier management. How it affects compliance: these are the controls an inspector expects to see after a contact-material event, and having them in place is what separates a controlled operation from a reactive one.

Material qualification confirms that a contact material is fit for its purpose and will not alter the product. Where the risk is significant, an extractables and leachables assessment, guided by standards such as USP chapters 661.1 and 661.2 for plastic materials and systems and USP 1663 and 1664 for extractables and leachables, characterizes what a material could release under real conditions. Change control ensures no contact material is substituted without evaluation, and supplier qualification ensures the component you approved is the component you receive. For a related contact-integrity failure, see our analysis of a container closure recall.

Contact-material control checklist

Use this checklist to test whether your contact-material controls would withstand an inspection after an event like this one.

• Inventory your contact materials. List every product contact surface, component, closure, and packaging material, with its specified material of construction.
• Confirm each is qualified. Verify that every contact material has documented qualification showing it is non reactive, non additive, and non absorptive for its use.
• Extend change control to materials. Ensure no contact material, gasket, liner, coating, or repair compound can be substituted without a formal change assessment.
• Reach into maintenance. Confirm that maintenance and engineering use only qualified contact materials, and that repairs with resin or epoxy are controlled.
• Qualify your suppliers. Confirm that component and material suppliers are qualified and that incoming materials match the approved specification.
• Assess extractables and leachables. Where the risk warrants it, hold an extractables and leachables assessment aligned with the relevant USP chapters.
• Test your investigation process. Confirm your deviation and investigation procedure would drive material identification before assuming a cause.
• Rehearse the recall. Confirm you can identify, reach, and reconcile all affected units quickly if a contact-material defect is found.

Common mistakes to avoid

• Treating it as a cleaning problem. Contact-material contamination is a materials and change control issue, not a residue from the previous product.
• Stopping the investigation at the lot. Recalling the affected lot without finding why the material entered leaves the system weakness in place.
• Forgetting maintenance materials. Epoxy, resin, sealants, and lubricants used in repairs are contact materials and need the same control as production components.
• Relying on release testing. Standard release tests are not designed to find a localized contact-material contaminant.
• Approving a supplier once and forgetting it. A qualified supplier can change a component or subcontractor, so qualification has to be maintained, not granted once.

Frequently asked questions

Why was Novo-Gesic Forte recalled?

Teva Canada recalled one lot of Novo-Gesic Forte 500 mg acetaminophen because it may contain phenolic resin or epoxy. Health Canada classified the recall as Type I because ingesting the material could injure the digestive system.

What is a Type I recall in Canada?

A Type I recall is the most serious class. Health Canada assigns it when there is a reasonable probability that the use of, or exposure to, a product will cause serious adverse health consequences or death. Type II and Type III cover progressively lower levels of risk.

How does phenolic resin or epoxy get into a tablet?

These materials are used in equipment coatings, tank and pipe linings, filter housings, gaskets, closure liners, and repair compounds. If a material is the wrong grade, degrades, is incompletely cured, or is introduced during an uncontrolled repair, it can shed particles or leach into product.

What GMP requirement applies to contact materials?

Product contact surfaces, containers, and closures must not be reactive, additive, or absorptive. In the United States this is set out in 21 CFR 211.65 and 211.94. In Canada it sits in Division 2 of the Food and Drug Regulations and is explained in Health Canada's GMP guide, GUI-0001.

Can end product testing catch a contact-material contaminant?

Usually not reliably. A contact-material contaminant is often localized and intermittent, so a standard release testing plan can pass a batch that still contains it. The effective controls are material qualification, change control, and supplier qualification, applied before production.

What should a manufacturer do after a recall like this?

Run a structured investigation that identifies the material, maps every contact point, and finds the failed control, then implement corrective and preventive action that addresses root cause. Extend change control to maintenance materials and requalify affected suppliers and components.

How MFLRC can help

MFLRC helps pharmaceutical manufacturers and packagers close the gaps that lead to contact-material recalls. Our quality assurance and validation teams can review your equipment and packaging material qualification, extend change control into maintenance and engineering, and build the extractables and leachables assessments your risk profile calls for. When a deviation or recall does occur, we help you run a defensible root cause investigation and corrective and preventive action programme that stands up to a Health Canada inspection.

We also run mock inspections and gap assessments so you find a contact-material weakness before an inspector or a recall does. Whether you manufacture solid oral doses, sterile products, or natural health products, we can map your contact-material controls to GMP expectations and help you build the evidence that they work.

Conclusion

The Novo-Gesic Forte recall is a reminder that a drug can fail not because of what is in the formula but because of what the product touched. Contact-material control is one of the oldest requirements in good manufacturing practice, yet it is easy to let it slip into the background behind cleaning, cross contamination, and line clearance. The manufacturers who avoid this failure are the ones who qualify every contact material, govern every change including in maintenance, and keep their supplier qualification current. If solid dose, sterile, or natural health products sit in your operation, now is the time to confirm that the materials touching your product cannot become your next recall. For related reading, see our analysis of a packaging line failure and of a cleaning validation recall.

Sources and references

Health Canada recall: Generic acetaminophen by Teva recalled because it may contain foreign material (Novo-Gesic Forte 500 mg)

21 CFR 211.65: Equipment construction (US Electronic Code of Federal Regulations)

21 CFR 211.94: Drug product containers and closures (US Electronic Code of Federal Regulations)

Health Canada: Good Manufacturing Practices Guide for Drug Products (GUI-0001)

United States Pharmacopeia: general chapters on packaging materials and extractables and leachables